A randomized phase 2 clinical trial of docetaxel with or without PF-3512676 [agatolimod] as first-line treatment of patients with advanced breast cancer

Trial Profile

A randomized phase 2 clinical trial of docetaxel with or without PF-3512676 [agatolimod] as first-line treatment of patients with advanced breast cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 May 2015

At a glance

  • Drugs Agatolimod (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Nov 2007 Status changed from in progress to withdrawn prior to recruitment.
    • 28 Aug 2007 Status changed from initiated to in progress.
    • 18 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top